Table 2. Incidence Rate Ratio of Cancer in Warfarin Users vs Nonusers.
| Cancer Site | IRR (95% CI) |
|---|---|
| All cancers | 0.84 (0.82-0.86) |
| Prostate | 0.69 (0.65-0.72) |
| Lung | 0.80 (0.75-0.86) |
| NSCLC | 0.80 (0.74-0.87) |
| SCLC | 0.71 (0.59-0.86) |
| Colon | 0.99 (0.93-1.06) |
| Breast | 0.90 (0.82-1.00) |
| Ductal | 0.90 (0.81-1.02) |
| Lobular | 1.00 (0.75-1.32) |
| Skina | 1.09 (1.01-1.18) |
| Gynecological | 0.85 (0.74-0.97) |
| Ovary | 0.81 (0.65-1.02) |
| Uterus | 0.91 (0.77-1.08) |
| Cervix | 1.03 (0.69-1.54) |
| Vulva and vagina | 0.64 (0.39-1.04) |
| Bone marrow | 1.00 (0.91-1.10) |
| Leukemia | 0.99 (0.89-1.11) |
| CLL | 0.89 (0.71-1.11) |
| AML | 0.70 (0.51-0.98) |
| Bladder | 0.82 (0.75-0.90) |
| Malignant melanoma | 0.96 (0.87-1.07) |
| Rectum and anus | 0.77 (0.69-0.86) |
| Rectum | 0.76 (0.68-0.85) |
| Anus | 0.90 (0.51-1.58) |
| Lymphoma | 0.92 (0.82-1.04) |
| Hodgkin | 0.66 (0.34-1.26) |
| Non-Hodgkin | 0.92 (0.81-1.04) |
| Brain | 0.74 (0.64-0.87) |
| Astrocytoma | 0.75 (0.57-0.98) |
| Meningioma | 0.66 (0.51-0.86) |
| Glioblastoma | 0.75 (0.56-1.00) |
| Kidney and ureters | 0.93 (0.82-1.06) |
| Kidney | 0.96 (0.84-1.10) |
| Pancreas | 0.92 (0.80-1.04) |
| Stomach | 0.77 (0.65-0.90) |
| Head and neck | 0.64 (0.51-0.81) |
| Tongue | 0.30 (0.16-0.56) |
| Throat | 0.59 (0.39-0.90) |
| Larynx | 0.75 (0.55-1.04) |
| Salivary gland | 1.34 (0.74-2.41) |
| Mouth | 0.80 (0.56-1.14) |
| Esophagus | 1.03 (0.83-1.27) |
| Gallbladder | 0.94 (0.71-1.24) |
| Endocrine glandsb | 0.53 (0.36-0.80) |
| Thyroid | 0.81 (0.56-1.18) |
Abbreviations: AML, acute myeloid leukemia; CLL, chronic lymphatic leukemia; IRR, incidence rate ratio (adjusted for sex and age); NSCLC, non–small-cell lung cancer; SCLC, small-cell lung cancer.
a
Excluding malignant melanoma and basal cell carcinoma.
b
Excluding thyroid.